Cholesterol lowering with atorvastatine for the prevention of gallstones following bariatric surgery (CHOLSTONE): an investigator- blinded randomised controlled trial

2025-524191-38-00 · tracked via the Priya Life Science EU tracker

Sponsor

Spaarne Gasthuis Stichting

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Nutritional and Metabolic Diseases

Decision date

17/03/2026

Enrollment target

202

Sites

Netherlands

Condition studied

Gallstones (chole(cysto)lithiasis) following bariatric surgery

Investigational medicinal product(s)

ATORVASTATIN

Eligibility

Age group

18-64 years

Sex

Female, Male

Primary endpoint

Incidence of gallstone formation six months after bariatric surgery, confirmed by ultrasound examination.

Endpoint detail

Change in plasma LDL-cholesterol levels between baseline and six months after bariatric surgery., Change in fecal and plasma bile acid profiles between baseline and six months after bariatric surgery., Incidence and severity of adverse events related to atorvastatin in the post- bariatric population

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524191-38-00 on CTIS ↗ ← All trials in the EU